Extended Data Fig. 4: MCT1 inhibition with AZD3965 impairs metastasis without altering markers of epithelial-to-mesenchymal transition.
From: Metabolic heterogeneity confers differences in melanoma metastatic potential
Related to Fig. 2. a, b, Flow cytometry histograms of anti-E-cadherin (a) and anti-N-cadherin (b) staining in melanoma cells from subcutaneous tumours of mice treated with DMSO (control) or AZD3965. Human keratinocytes were included as a control in each case as they are known to include subpopulations of E-cadherin- and N-cadherin-positive cells. In xenografts, human melanoma cells were distinguished from mouse cells based on positivity for HLA-ABC and DsRed and negativity for mouse CD31, CD45 and Ter119 staining (see Extended Data Fig. 9e, f for gating strategy). Data are representative of two to three mice analysed in two independent experiments. c, Western blot analysis of vimentin in subcutaneous tumours from NSG mice treated with DMSO or AZD3965.
